NCT01517451

Radiation and Androgen Ablation for Prostate Cancer

Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
• Sex: Male
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

A study to see how effective and tolerable radiation therapy along with androgen deprivation therapy is in treating prostate cancer.

Detailed description

This will be a Phase I/II study evaluating the effectiveness and toxicity of a combined regimen of 7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions) with androgen deprivation therapy (ADT) for 4 months total.

Conditions

• Adenocarcinoma of the Prostate

Interventions

Type	Name	Description
RADIATION	Radiation Therapy	7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions)
DRUG	Androgen Deprivation Therapy (ADT)	Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.

Timeline

• Start date: 2013-05-22
• Primary completion: 2024-02-28
• Completion: 2025-12-31
• First posted: 2012-01-25
• Last updated: 2026-02-11
• Results posted: 2026-02-11

Locations

3 sites across 1 country: United States